In vitro ADME profiling, bioanalysis services, and dedicated assay development and compound screening

Quintara Discovery, now part of Frontage Laboratories, Inc., specializes in drug discovery and development services, particularly focusing on in vitro ADME (Absorption, Distribution, Metabolism, Excretion) profiling and bioanalysis. Their offerings include both GLP (Good Laboratory Practice) and non-GLP bioanalytical services, which are essential for guiding decision-making in drug development and regulatory submissions. The company emphasizes a customer-centric approach, aiming to deliver high-quality results efficiently while integrating closely with clients' teams. Their extensive capabilities in assay development and compound screening are designed to accelerate the drug discovery process, ensuring that clients receive tailored solutions that meet their specific needs.

In addition to their core services, Quintara Discovery employs advanced technologies and methodologies for method development and validation, ensuring compliance with regulatory standards. Their bioanalytical services encompass a wide range of studies, including pharmacokinetic and toxicokinetic analyses, as well as drug-drug interaction and bioequivalence studies. The company utilizes state-of-the-art equipment such as mass spectrometers and high-performance liquid chromatography (HPLC) systems to provide accurate and reliable data across various biological matrices. Their rigorous quality assurance protocols and comprehensive documentation practices further reinforce their commitment to delivering high-quality, reliable results in the pharmaceutical and biotech sectors.

United States

Quintara Discovery is a Contract Research Organization that supports biotech, pharma, and academic organizations in pre-clinical space for molecule discovery and development.

Quintara Discovery

Company Details